Hanmeng Xu

Hanmeng Xu

Auto-generated profile, based on publicly available information

Hanmeng Xu

Department of Epidemiology, Johns Hopkins University , Baltimore, Maryland , USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2023 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
KWKirsten Wiens
Kirsten Wiens
HXHanmeng Xu
Hanmeng Xu
KZKaiyue Zou
Kaiyue Zou
JMJohn Mwaba
John Mwaba
JLJustin Lessler
Justin Lessler
AAAndrew S. Azman
Andrew S. Azman
Background: Cholera surveillance relies on clinical diagnosis of acute watery diarrhea. Suspected cholera case definitions have high sensitivity but low specificity, challenging our ability to characterize cholera burden and epidemiology. Our objective was to estimate the proportion of clinically suspected cholera that are trueVibrio choleraeinfections and identify factors that explain variation in positivity.Methods and findings: We conducted a systematic review of studies that tested ≥10 suspected cholera cases forV.choleraeO1/O139 using culture, PCR, and/or a rapid diagnostic test. We searched PubMed, Embase, Scopus, and Google Scholar for studies that sampled at least one suspected case between January 1, 2000 and April 19, 2023, to reflect contemporary patterns inV.choleraepositivity. We estimated diagnostic test sensitivity and specificity using a latent class meta-analysis. We estimatedV.choleraepositivity using a random-effects meta-analysis, adjusting for test performance. We included 119 studies from 30 countries.V.choleraepositivity was lower in studies with representative sampling and in studies that set minimum ages in suspected case definitions. After adjusting for test performance, on average, 52% (95% credible interval (CrI): 24%, 80%) of suspected cases represented trueV.choleraeinfections. After adjusting for test performance and study methodology, the odds of a suspected case having a true infection were 5.71 (odds ratio 95% CrI: 1.53, 15.43) times higher when surveillance was initiated in response to an outbreak than in non-outbreak settings. Variation across studies was high, and a limitation of our approach was that we were unable to explain all the heterogeneity with study-level attributes, including diagnostic test used, setting, and case definitions.Conclusions: In this study, we found that burden estimates based on suspected cases alone may overestimate the incidence of medically attended cholera by 2-fold. However, accounting for cases missed by traditional clinical surveillance is key to unbiased cholera burden estimates. Given the substantial variability in positivity between settings, extrapolations from suspected to confirmed cases, which is necessary to estimate cholera incidence rates without exhaustive testing, should be based on local data.

2 June 2021 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
SZSophia Alison Zweig
Sophia Alison Zweig
AZAlexander John Zapf
Alexander John Zapf
HXHanmeng Xu
Hanmeng Xu
QLQingfeng Li
Qingfeng Li
SASmisha Agarwal
Smisha Agarwal
DPDavid H Peters
David H Peters
Background: The United States of America has the highest global number of COVID-19 cases and deaths, which may be due in part to delays and inconsistencies in implementing public health and social measures (PHSMs).Objective: In this descriptive analysis, we analyzed the epidemiological evidence for the impact of PHSMs on COVID-19 transmission in the United States and compared these data to those for 10 other countries of varying income levels, population sizes, and geographies.Methods: We compared PHSM implementation timing and stringency against COVID-19 daily case counts in the United States and against those in Canada, China, Ethiopia, Japan, Kazakhstan, New Zealand, Singapore, South Korea, Vietnam, and Zimbabwe from January 1 to November 25, 2020. We descriptively analyzed the impact of border closures, contact tracing, household confinement, mandated face masks, quarantine and isolation, school closures, limited gatherings, and states of emergency on COVID-19 case counts. We also compared the relationship between global socioeconomic indicators and national pandemic trajectories across the 11 countries. PHSMs and case count data were derived from various surveillance systems, including the Health Intervention Tracking for COVID-19 database, the World Health Organization PHSM database, and the European Centre for Disease Prevention and Control.Results: Implementing a specific package of 4 PHSMs (quarantine and isolation, school closures, household confinement, and the limiting of social gatherings) early and stringently was observed to coincide with lower case counts and transmission durations in Vietnam, Zimbabwe, New Zealand, South Korea, Ethiopia, and Kazakhstan. In contrast, the United States implemented few PHSMs stringently or early and did not use this successful package. Across the 11 countries, national income positively correlated (r=0.624) with cumulative COVID-19 incidence.Conclusions: Our findings suggest that early implementation, consistent execution, adequate duration, and high adherence to PHSMs represent key factors of reducing the spread of COVID-19. Although national income may be related to COVID-19 progression, a country’s wealth appears to be less important in controlling the pandemic and more important in taking rapid, centralized, and consistent public health action.

1 February 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
PBPatrick Musole Bugeme
Patrick Musole Bugeme
HXHanmeng Xu
Hanmeng Xu
CHChloe Hutchins
Chloe Hutchins
JDJuan Dent
Juan Dent
JSJaime Mufitini Saidi
Jaime Mufitini Saidi
EMEspoir Bwenge Malembaka
Espoir Bwenge Malembaka
Our understanding of the burden and drivers of cholera mortality is hampered by limited surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of Congo, we describe cholera deaths across 3 epidemics between September 2021 and September 2023 following mass vaccination.

6 October 2022 in medRxiv
Verified
Preprint
Open access
PDF file
KWKirsten Wiens
Kirsten Wiens
HXHanmeng Xu
Hanmeng Xu
KZKaiyue Zou
Kaiyue Zou
JMJohn Mwaba
John Mwaba
JLJustin Lessler
Justin Lessler
AAAndrew S. Azman
Andrew S. Azman
Background: Cholera surveillance relies on clinical diagnosis of acute watery diarrhea. Suspected cholera case definitions have high sensitivity but low specificity, challenging our ability to characterize cholera burden and epidemiology. Our objective was to estimate the proportion of clinically suspected cholera that are true Vibrio cholerae infections and identify factors that explain variation in positivity. Methods: We conducted a systematic review of studies from 2000-2023 that tested ≥10 suspected cholera cases for V. cholerae O1/O139 using culture, PCR and/or a rapid diagnostic test. We searched PubMed, Embase, Scopus, and Google Scholar on October 16, 2021 and updated the search on April 19, 2023. We estimated diagnostic test sensitivity and specificity using a latent class meta-analysis. We estimated V. cholerae positivity using a random-effects meta-analysis, adjusting for test performance. Findings: We included 119 studies from 30 countries. V. cholerae positivity was lower in studies with representative sampling and lower minimum ages in suspected case definitions. After adjusting for test performance, on average 52% (95% Credible Interval: 24%, 80%) of suspected cases represented true V. cholerae infections. After adjusting for test performance and study methodology, odds of a suspected case having a true infection were 5.71 (Odds ratio 95% Credible Interval: 1.53, 15.43) times higher when surveillance was initiated in response to an outbreak than in non-outbreak settings. Variation across studies was high and a limitation of our approach and the resolution of the data was that we were unable to explain all the heterogeneity with study-level attributes, including diagnostic test used, setting, and case definitions. Conclusions: In this study, we found that burden estimates based on suspected cases alone may overestimate the incidence of medically attended cholera by twofold. However, accounting for cases missed by traditional clinical surveillance is key to unbiased cholera burden estimates. Given the substantial variability in positivity between settings, extrapolations from suspected to confirmed cases, which is necessary to estimate cholera incidence rates without exhaustive testing, should be based on local data. Funding for this study was provided by the Bill and Melinda Gates Foundation and the National Institute of Allergy and Infectious Disease. Author Summary: Why was this study done?: Cholera surveillance typically relies on the clinical diagnosis of acute watery diarrhea (i.e., “suspected cholera”), but this definition has a low specificity for cholera. Our goal was to estimate the proportion of suspected cholera cases that are true Vibrio cholerae infections and identify factors that contribute to variation in observed positivity. What did the researchers do and find?: We conducted a systematic review of studies from 2000-2023 that tested suspected cholera cases for V. cholerae infection using one of three different laboratory tests. We included 119 studies from 30 countries and found that, on average, half of suspected cholera cases represented true V. cholerae infections, after accounting for laboratory test accuracy. We also found high variability between studies and that the odds of a suspected case being a true infection were higher during outbreaks compared to non-outbreak settings. What do these findings mean?: Our findings suggest that burden estimates based solely on suspected cases may overestimate the incidence of medically attended cholera by twofold. A limitation of our approach was that we couldn’t account for cases missed by clinical surveillance, which is crucial for unbiased overall cholera burden estimates and an important area for future work. The high variability across studies suggests also that local testing data should be used to inform assumptions about positivity when exhaustive testing is not feasible.

12 February 2021 in JMIR Preprints
Verified
Preprint
Open access
SZSophia Alison Zweig
Sophia Alison Zweig
AZAlexander John Zapf
Alexander John Zapf
HXHanmeng Xu
Hanmeng Xu
QLQingfeng Li
Qingfeng Li
SASmisha Agarwal
Smisha Agarwal
DPDavid H Peters
David H Peters
BACKGROUND The United States of America has the highest global number of COVID-19 cases and deaths, which may be due in part to delays and inconsistencies in implementing public health and social measures (PHSMs). OBJECTIVE In this descriptive analysis, we analyzed the epidemiological evidence for the impact of PHSMs on COVID-19 transmission in the United States and compared these data to those for 10 other countries of varying income levels, population sizes, and geographies. METHODS We compared PHSM implementation timing and stringency against COVID-19 daily case counts in the United States and against those in Canada, China, Ethiopia, Japan, Kazakhstan, New Zealand, Singapore, South Korea, Vietnam, and Zimbabwe from January 1 to November 25, 2020. We descriptively analyzed the impact of border closures, contact tracing, household confinement, mandated face masks, quarantine and isolation, school closures, limited gatherings, and states of emergency on COVID-19 case counts. We also compared the relationship between global socioeconomic indicators and national pandemic trajectories across the 11 countries. PHSMs and case count data were derived from various surveillance systems, including the Health Intervention Tracking for COVID-19 database, the World Health Organization PHSM database, and the European Centre for Disease Prevention and Control. RESULTS Implementing a specific package of 4 PHSMs (quarantine and isolation, school closures, household confinement, and the limiting of social gatherings) early and stringently was observed to coincide with lower case counts and transmission durations in Vietnam, Zimbabwe, New Zealand, South Korea, Ethiopia, and Kazakhstan. In contrast, the United States implemented few PHSMs stringently or early and did not use this successful package. Across the 11 countries, national income positively correlated (r=0.624) with cumulative COVID-19 incidence. CONCLUSIONS Our findings suggest that early implementation, consistent execution, adequate duration, and high adherence to PHSMs represent key factors of reducing the spread of COVID-19. Although national income may be related to COVID-19 progression, a country’s wealth appears to be less important in controlling the pandemic and more important in taking rapid, centralized, and consistent public health action.

9 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
EMEspoir Bwenge Malembaka
Espoir Bwenge Malembaka
PBPatrick Musole Bugeme
Patrick Musole Bugeme
CHChloe Hutchins
Chloe Hutchins
HXHanmeng Xu
Hanmeng Xu
JHJuan Dent Hulse
Juan Dent Hulse
AAAndrew S Azman
Andrew S Azman
Background: A global shortage of cholera vaccines has increased the use of single-dose regimens, rather than the standard two-dose regimen. There is limited evidence on single-dose protection, particularly in children. In 2020, a mass vaccination campaign resulting in largely single dose coverage, was conducted in Uvira, an endemic urban setting in eastern Democratic Republic of the Congo. We examined the effectiveness of a single-dose of the oral cholera vaccine Euvichol-Plus ® in this high-burden setting. Methods: We recruited medically attended confirmed cholera cases and age-, sex-, and neighborhood-matched community controls during two distinct periods after mass vaccination, October 2021 to March 2022 (12–17 months post-vaccination) and October 2022 to October 2023 (24–36 months post-vaccination). The odds of vaccination in cases and controls were contrasted in conditional logistic regression models to estimate unadjusted and adjusted vaccine effectiveness. Findings: We enrolled 658 confirmed cases and 2,274 matched controls during the two study periods with 15·0% of cases being under five years old at the time of vaccination. The adjusted single-dose VE was 52·7% (95% CI: 31·4–67·4) 12–17 months post-vaccination and 45·5% (95% CI: 25·8– 60·0) 24–36 months post-vaccination. While protection in the first 12–17 months post-vaccination was similar for 1–4-year-olds and older individuals, over the third year post-vaccination the estimate of protection in 1–4 year-olds (adjusted VE 33·1%; 95% CI: -30·0–65·6) appeared to wane with confidence intervals spanning the null. Interpretation: A single-dose of Euvichol-Plus ® provided substantial protection against medically attended cholera for at least 36 months post-vaccination in this cholera endemic setting. While our evidence provides support for comparable levels of protection in young children and others in the short-term, protection among young children may wane significantly by the third year after vaccination. Funding: Wellcome Trust and Gavi (GAVI-RFP-2019-062). Research in context: Evidence before this study: In late 2022, due to increasing demand for killed, whole-cell, oral cholera vaccines (kOCV) and limited production capacity, the International Coordinating Group (the organization managing emergency stocks of kOCVs) changed policy to deploy single-dose, rather than the standard two-dose regimen, for emergency vaccination campaigns. This decision was in line with WHO guidance on the use of a single dose in outbreaks, where short-term protection is key. However, this recommendation is based on a limited number of clinical studies with short-term follow-up. There is also limited evidence on the magnitude and duration of protection conferred by a single dose of kOCV, particularly in children under five years of age. We searched PubMed for randomized trials and observational studies published in English before November 1, 2023, that reported estimates of protection conferred by a single dose of kOCV, using the term “(effectiveness OR efficacy) AND cholera* AND vaccine”. We found no published studies estimating the effectiveness of a single dose of Euvichol-Plus ® , and only one study reporting two-dose effectiveness. Despite this paucity of evidence, this is the only vaccine currently available in the global stockpile. To date, there has been one randomized trial conducted in Bangladesh between 2014 and 2016, and seven observational studies conducted between 2009 and 2016 in Guinea, Haiti, India, Malawi, Sudan, Zambia and Zanzibar, reporting effectiveness estimates of a single dose of the current generation of kOCV. Aside from the trial in Bangladesh, all estimates were based on secondary analyses that the studies were not powered to estimate. The Bangladesh trial is the only study to date that provides an age-stratified estimate of single-dose protection, and while it found an overall protective efficacy of 62% (95% CI: 43– 75) during the 2-year follow up for individuals aged five years or older, it found no significant protection conferred by the Shanchol kOCV (a bioequivalent of Euvichol-Plus ® ) for individuals under five years of age (protective efficacy: -44%, 95% CI -220 to 35). Four of the seven observational studies provide single-dose vaccine effectiveness (VE) estimates only during the first 12 months post-vaccination with estimates ranging from 43% (95% CI -84-82) in Guinea to 93% (95% CI 69-98) in Haiti. The three other observational studies providing a single dose VE estimate between 12-30 months post-vaccination were unable to demonstrate statistically significant protection conferred by kOCV, with estimates ranging between 32·5% (95% CI - 318·0-89·1) in India and 40% (95% CI -31-73) in Haiti. No vaccine protection estimates have been published from the two identified cholera endemic foci in Africa, the Democratic Republic of the Congo and Nigeria. Added value of this study: In this vaccine effectiveness study, we show that a single dose of Euvichol-Plus ® vaccine can provide significant protection against medically attended cholera for up to 36 months after vaccination in a cholera endemic setting in Africa, though protection in children under five years old remains unclear. These estimates help fill critical gaps in our understanding of the magnitude and duration of protection from a single dose of the most widely used kOCV, Euvichol-Plus ® and is one of only a few studies to measure protection in an endemic setting in Africa. Implications of all the available evidence: The corpus of available evidence suggests that use of a single dose of kOCV in emergency situations where cholera is endemic, like Uvira, is justified and that providing a second dose within the first 12-24 months post-vaccination may only provide marginal benefit to the general population. However, more evidence and analyses are needed to weigh the costs and benefits of tailored vaccination approaches for those under five years old, including possibility of providing a second dose at an earlier timepoint.